Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.
Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback